Redx Pharma plc Redx to present two posters at AACR 2019
March 29 2019 - 3:02AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
29 March 2019
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma to present two posters at the 2019 American
Association for Cancer Research (AACR) Annual Meeting
Posters show that RXC004 has the ability to directly target
tumour growth and stimulate the host immune response against
tumours
Alderley Park, 29 March 2019 - Redx Pharma (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that the two abstracts submitted by the Company have been
accepted for presentation as posters at the 2019 American
Association for Cancer Research (AACR) Annual Meeting in Atlanta,
Georgia, taking place between 29 March and 3 April 2019.
Both posters relate to the Company's lead oncology candidate,
RXC004, a selective, orally bioavailable porcupine (PORCN)
inhibitor which targets the Wnt signalling pathway. The posters
present preclinical data confirming the potential for RXC004 in
modulating the immune system of the tumour microenvironment (poster
#506) as well as preclinical data on the direct tumour-targeting
effects of RXC004 in genetically-defined models of cancer (poster
#3874).
Redx is evaluating RXC004 in an ongoing first-in-man clinical
trial. The trial is a modular, multi-arm, multi-part, Phase 1/2a,
adaptive design study whose primary objective is to evaluate the
safety and tolerability of the drug in patients with advanced
malignancies (ClinicalTrials.gov Identifier: NCT03447470).
Richard Armer, Chief Scientific Officer of Redx Pharma plc
commented, "We are delighted to be presenting again at this
high-profile cancer conference. These poster presentations
demonstrate our continued understanding of how RXC004 is able to
have both direct and immunomodulatory effects on tumours in various
preclinical cancer models. This preclinical data will inform design
of future clinical studies to investigate the full potential of
this mechanism."
Details of the poster presentations are as follows:
1)
Abstract Title: Wnt/<BETA>-Catenin pathway inhibitor
RXC004 enhances the immunity
of pre-clinical models of cancer
Session Title: Metabolic Mechanisms That Modulate
the Immune Response to Cancer
Date/Time: March 31, 2019, 1:00 PM - 5:00
PM CST
Location: Poster Section 21
Poster Board Number: 5
Poster Number: 506
2)
Abstract Title: Efficacy of the Wnt/Beta-Catenin
pathway inhibitor RXC004 in
genetically-defined models of
cancer
Session Title: Novel Antitumor Agents 2
Date/Time: April 2, 2019, 1:00 PM - 5:00
PM CST
Location: Poster Section 12
Poster Board Number: 24
Poster Number: 3874
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
920
Lisa Anson, Chief Executive Officer
Andrew Saunders, Chief Medical Officer
Cantor Fitzgerald Europe (Nominated Advisor & T: +44 20 7894
Joint Broker) 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx is a UK-based biotechnology company whose shares are traded
on AIM (AIM:REDX). Redx's vision is to become a leading biotech
focused on the development of novel precision medicines that have
the potential to transform treatment in oncology and fibrotic
diseases.
If you would like to sign up to regular alerts from Redx Pharma,
please follow this link
https://www.redxpharma.com/investors/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAVVLFLKXFLBBF
(END) Dow Jones Newswires
March 29, 2019 03:02 ET (07:02 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024